secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001171843-25-001020
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge
--------------------------------------------------------------------------------

- Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).
- FY 2024 GAAP operating loss $2.5M; non-GAAP operating profit $62.9M (excl. stock-based comp).
- FY 2025 ORLADEYO revenue guidance raised to $535-550M from $515-535M; expects positive EPS in 2H 2025.
- Annora Pharma filed ANDA for generic ORLADEYO; company intends to vigorously defend three patents expiring 2039.
- NDA submission in 2025 for pediatric ORLADEYO granule (ages 2-11); initial data from BCX17725 and avoralstat expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/0001171843-25-001020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/f8k_022425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer